Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 163

The DOI matches its Crossref record.

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

Open access
Vega-Ruiz, Arturo, Cortes, Jorge E., Sever, Matjaz, Manshouri, Taghi, Quintás-Cardama, Alfonso, Luthra, Raja, Kantarjian, Hagop M., Verstovsek, Srdan · 2009 · Leukemia Research

Abstract

Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003–2005 in phase II clinical trial with imatinib mesylate (400mg daily), a KIT inhibitor. Median time on therapy was 9 months (range, 0.5 – 44+). Only 1 patient, with D816V KIT mutation-negative FIP1L1-PDGFRα-negative SM-HES, achieved complete remission (now lasting for 44 months). Six other patients reported symptomatic improvement, including 2 with D816V KIT mutation-positive SM (one reported improvement in diarrhea and the other in fatigue). Other patients had no benefit. Imatinib was relatively well tolerated. Our study confirms that imatinib therapy does not result in appreciable clinical activity in patients with D816V mutation-positive SM, but may result in a significant benefit in occasional patient with D816V mutation-negative SM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.leukres.2008.12.020

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 163

Metadata

Authors
Vega-Ruiz, A., Cortes, J. E., Sever, M., Manshouri, T., Quintás-Cardama, A., Luthra, R., Kantarjian, H. M., & Verstovsek, S.
Venue
Leukemia Research
Publisher
Elsevier BV
Published
2009-11
Volume
33
Issue
11
Pages
1481-1484
ISSN
0145-2126 (ISSN-L)
OpenAlex
W2126677578
Cited by
163
References
0
FWCI
4.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. https://app.cochat.ai/papers/10.1016/j.leukres.2008.12.020
The paper
Vega-Ruiz, A., Cortes, J. E., Sever, M., Manshouri, T., Quintás-Cardama, A., Luthra, R., Kantarjian, H. M., & Verstovsek, S. (2009). Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leukemia Research. https://doi.org/10.1016/j.leukres.2008.12.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.